Literature DB >> 7547508

Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide.

R Pellegrini1, A Mariotti, E Tagliabue, R Bressan, G Bunone, D Coradini, G Della Valle, F Formelli, L Cleris, P Radice.   

Abstract

The retinoid N-(hydroxyphenyl) retinamide (4-HPR) appears to be a promising tool for chemoprevention of breast carcinoma, and clinical trials to evaluate its effect are in progress. However, its action on tumor cells has remained largely undefined. We report here that 4-HPR induced apoptosis and/or differentiation in breast cancer cell lines, independent of hormone receptor status and retinoic acid receptor expression, although it was slightly more efficient in inhibiting proliferation of estrogen receptor-positive cells. 4-HPR up-modulated expression of several differentiation markers (class 1 HLA, laminin, and beta 1 integrin chain) and down-regulated expression of molecules associated with tumor progression, including the p185/HER2 oncoprotein, the epidermal growth factor receptor, and the M(r) 67,000 laminin receptor. These data suggest that 4-HPR could exert a beneficial effect by inhibiting cell proliferation and modulating breast tumor aggressiveness.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547508

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  12 in total

Review 1.  Novel agents for chemoprevention, screening methods, and sampling issues.

Authors:  Mary Jo Fackler; Ella Evron; Seema A Khan; Saraswati Sukumar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

2.  Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells.

Authors:  Y Liu; M O Lee; H G Wang; Y Li; Y Hashimoto; M Klaus; J C Reed; X Zhang
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

3.  BBC3 mediates fenretinide-induced cell death in neuroblastoma.

Authors:  Jun S Wei; Craig C Whiteford; Nicola Cenacchi; Chang Gue Son; Javed Khan
Journal:  Oncogene       Date:  2005-12-01       Impact factor: 9.867

4.  Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).

Authors:  M M Webber; D Bello-DeOcampo; S Quader; N D Deocampo; W S Metcalfe; R M Sharp
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

5.  Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

Authors:  Andrea Decensi; Chris Robertson; Aliana Guerrieri-Gonzaga; Davide Serrano; Massimiliano Cazzaniga; Serena Mora; Marcella Gulisano; Harriet Johansson; Viviana Galimberti; Enrico Cassano; Simona M Moroni; Franca Formelli; Ernst A Lien; Giuseppe Pelosi; Karen A Johnson; Bernardo Bonanni
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

6.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.

Authors:  G Bunone; P A Briand; R J Miksicek; D Picard
Journal:  EMBO J       Date:  1996-05-01       Impact factor: 11.598

7.  Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.

Authors:  Debbie C Koay; Cynthia Zerillo; Murli Narayan; Lyndsay N Harris; Michael P DiGiovanna
Journal:  Breast Cancer Res       Date:  2010-08-09       Impact factor: 6.466

8.  Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma.

Authors:  Roos Cuperus; René Leen; Godelieve A M Tytgat; Huib N Caron; André B P van Kuilenburg
Journal:  Cell Mol Life Sci       Date:  2009-11-26       Impact factor: 9.261

9.  Combinational treatment with retinoic acid derivatives in non-small cell lung carcinoma in vitro.

Authors:  Eun Jung Choi; Young Mi Whang; Seok Jin Kim; Hyun Jin Kim; Yeul Hong Kim
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

10.  Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells.

Authors:  E Dittrich; M Offterdinger; S M Schneider; Ch Dittrich; H Huber
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.